Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Field Evaluation of Novel Spatial Repellent Controlled Release Devices (CRDs) against Mosquitoes in an Outdoor Setting in the Northern Peruvian Amazon.

Tropical medicine and infectious disease·2022
Same author

Spatial repellents transfluthrin and metofluthrin affect the behavior of Dermacentor variabilis, Amblyomma americanum, and Ixodes scapularis in an in vitro vertical climb assay.

PloS one·2022
Same author

A combined experimental-computational approach for spatial protection efficacy assessment of controlled release devices against mosquitoes (Anopheles).

PLoS neglected tropical diseases·2019
Same author

Correction to: Rapid reconstitution packages (RRPs) for stable storage and delivery of glucagon.

Drug delivery and translational research·2019
Same author

Rapid reconstitution packages (RRPs) for stable storage and delivery of glucagon.

Drug delivery and translational research·2019
Same author

Controlled release spatial repellent devices (CRDs) as novel tools against malaria transmission: a semi-field study in Macha, Zambia.

Malaria journal·2018

Related Experiment Video

Updated: May 21, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Pharmacogenomics-based RNA interference nanodelivery: focus on solid malignant tumors.

Yitzhak Rosen1, Urvashi M Upadhyay, Noel M Elman

  • 1Superior NanoBioSystems, Washington, DC, USA. yitzhakrosen@yahoo.com

Expert Opinion on Drug Delivery
|June 5, 2012
PubMed
Summary
This summary is machine-generated.

Nanoparticle delivery systems offer promise for in vivo RNA interference therapy. Pharmacogenomics can personalize treatments by predicting patient response to both small interfering RNA (siRNA) and delivery systems, improving outcomes.

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Related Experiment Videos

Last Updated: May 21, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Area of Science:

  • Biomedical Engineering
  • Pharmacogenomics
  • Nanotechnology

Background:

  • RNA interference (RNAi) is a potent therapeutic strategy, but in vivo application is hindered by the instability of small interfering RNA (siRNA).
  • Nanoparticles are promising nonviral carriers for siRNA delivery, offering unique properties and enabling surface modification for targeted delivery.
  • Toxicity and individualized responses to nanoparticle delivery systems require careful consideration and pharmacogenomic profiling.

Purpose of the Study:

  • To review the application of pharmacogenomics and toxicogenomics in nanoparticle-based drug delivery for small interfering RNA (siRNA).
  • To explore the potential of engineered nanoparticle delivery systems for personalized medicine in treating malignant tumors.

Main Methods:

  • Literature review encompassing pharmacogenomics, toxicogenomics, nanoparticle drug delivery, and siRNA.
  • Focus on the logical engineering of nanoparticle systems for targeted and personalized cancer therapy.

Main Results:

  • Pharmacogenomics can predict patient response to both siRNA gene silencing and nanoparticle delivery systems.
  • Assessing gene expression variations and single nucleotide polymorphisms aids in patient profiling.
  • Understanding toxicity profiles is crucial for patient compliance and treatment success.

Conclusions:

  • Pharmacogenomics is vital for tailoring RNA interference therapies, considering both the siRNA payload and the nanoparticle carrier.
  • Personalized patient profiling based on genetic variations and toxicity assessments is key to overcoming treatment failures.
  • Engineered nanoparticle delivery systems hold significant potential for personalized medicine in oncology.